Results 311 to 320 of about 510,929 (409)

Possibilities of Inner Ear Barrier Models for Otologic Drug Development

open access: yesAdvanced Therapeutics, EarlyView.
This review examines innovative organ chip models that reconstruct critical inner ear barriers, addressing a fundamental challenge in otologic drug development: the limited understanding of pharmaceutical behavior across these complex barriers. By replicating these barriers, the advanced models offer promising alternatives to traditional testing ...
Yeji Ahn   +7 more
wiley   +1 more source

Structural Characterization and AI‐Enhanced Modeling of a Broadly Neutralizing Camelid Antibody Against SARS‐CoV‐2 Variants

open access: yesAdvanced Therapeutics, EarlyView.
This study characterizes a camelid antibody (B10) with potent neutralizing activity against SARS‐CoV‐2 Wildtype and Omicron variants. Through binding assays, epitope mapping, pseudovirus neutralization, and AI‐driven modeling, the antibody is shown to target conserved RBD regions in a closed Spike conformation.
Katja Hanack   +13 more
wiley   +1 more source

Excessive DNA Double‐Strand Breaks–Associated 3D Genome Reorganization Contributes to Neural Tube Defects with Folate Deficiency

open access: yesAdvanced Science, EarlyView.
Neural tube defects (NTDs) are among the most common congenital malformations. However, the underlying etiology and mechanism remain elusive. Here, the role of DNA double‐strand breaks (DSBs) in 3D genome organization within the NTDs with folate deficiency is reported.
Ting Zhang   +12 more
wiley   +1 more source

Cuproptosis Signature Would Reveal the Acute‐Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder

open access: yesAdvanced Science, EarlyView.
Neuromyelitis optica spectrum disorder (NMOSD) has distinct acute‐remitting courses but lacks biomarkers for predicting relapse. Recent studies found cuproptosis‐related genes affect its course, and a model built accordingly can predict relapse to aid intervention.
Peidong Liu   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy